

HALOZYME THERAPEUTICS INC
Form 4
May 01, 2007

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Kelley Kenneth J

(Last) (First) (Middle)

C/O HALOZYME
THERAPEUTICS, INC., 11588
SORRENTO VALLEY RD., SUITE
17

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS
INC [HTI]

3. Date of Earliest Transaction
(Month/Day/Year)
04/30/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price |
| Common Stock | 04/30/2007 | | M ⁽¹⁾ | | 25,000 | A | \$ 4.1 |
| Common Stock | 04/30/2007 | | S ⁽¹⁾ | | 500 | D | \$ 10.2 |
| Common Stock | 04/30/2007 | | S ⁽¹⁾ | | 300 | D | \$ 10.21 |
| Common Stock | 04/30/2007 | | S ⁽¹⁾ | | 200 | D | \$ 10.22 |

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

| | | | | | | | |
|--------------|------------|------------------------|-------|---|----------|--------|---|
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 300 | D | \$ 10.23 | 38,700 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 800 | D | \$ 10.24 | 37,900 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 2,100 | D | \$ 10.25 | 35,800 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 200 | D | \$ 10.26 | 35,600 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 100 | D | \$ 10.27 | 35,500 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 800 | D | \$ 10.28 | 34,700 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 400 | D | \$ 10.29 | 34,300 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 4,800 | D | \$ 10.3 | 29,500 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 2,100 | D | \$ 10.31 | 27,400 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 1,000 | D | \$ 10.32 | 26,400 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 1,800 | D | \$ 10.33 | 24,600 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 800 | D | \$ 10.34 | 23,800 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 3,000 | D | \$ 10.35 | 20,800 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 800 | D | \$ 10.36 | 20,000 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 500 | D | \$ 10.37 | 19,500 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 3,850 | D | \$ 10.38 | 15,650 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 200 | D | \$ 10.39 | 15,450 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 200 | D | \$ 10.4 | 15,250 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 100 | D | \$ 10.48 | 15,150 | D |
| Common Stock | 04/30/2007 | <u>S⁽¹⁾</u> | 100 | D | \$ 10.49 | 15,050 | D |
| | 04/30/2007 | <u>S⁽¹⁾</u> | 50 | D | \$ 10.5 | 15,000 | D |

Common
Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | | |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--------------|----------------------------|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Option to Purchase Common Stock | \$ 4.1 | 04/30/2007 | | M ⁽¹⁾ | 25,000 | 05/21/2004 | 05/21/2014 | Common Stock | 25,000 |

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Kelley Kenneth J
C/O HALOZYME THERAPEUTICS, INC.
11588 SORRENTO VALLEY RD., SUITE 17
SAN DIEGO, CA 92121

X

Signatures

/s/ Kenneth J.
Kelley

05/01/2007

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares purchased and sold, as applicable, pursuant to 10b5-1 Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.